

Yu Sakurai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/758326/publications.pdf>

Version: 2024-02-01

54
papers

2,014
citations

279798

23
h-index

243625

44
g-index

56
all docs

56
docs citations

56
times ranked

2863
citing authors

#	ARTICLE	IF	CITATIONS
1	The RNA Sensor RIG-I Dually Functions as an Innate Sensor and Direct Antiviral Factor for Hepatitis B Virus. <i>Immunity</i> , 2015, 42, 123-132.	14.3	353
2	A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo. <i>Journal of Controlled Release</i> , 2012, 163, 267-276.	9.9	264
3	Gene Silencing via RNAi and siRNA Quantification in Tumor Tissue Using MEND, a Liposomal siRNA Delivery System. <i>Molecular Therapy</i> , 2013, 21, 1195-1203.	8.2	112
4	Endosomal escape and the knockdown efficiency of liposomal-siRNA by the fusogenic peptide shGALA. <i>Biomaterials</i> , 2011, 32, 5733-5742.	11.4	107
5	RNAi-mediated gene knockdown and anti-angiogenic therapy of RCCs using a cyclic RGD-modified liposomal-siRNA system. <i>Journal of Controlled Release</i> , 2014, 173, 110-118.	9.9	103
6	Heterogeneity of tumor endothelial cells and drug delivery. <i>Advanced Drug Delivery Reviews</i> , 2016, 99, 140-147.	13.7	88
7	Self-Degradable Lipid-Like Materials Based on Hydrolysis accelerated by the intra-Particle Enrichment of Reactant (HyPER) for Messenger RNA Delivery. <i>Advanced Functional Materials</i> , 2020, 30, 1910575.	14.9	65
8	An aptamer ligand based liposomal nanocarrier system that targets tumor endothelial cells. <i>Biomaterials</i> , 2014, 35, 7110-7120.	11.4	62
9	Remodeling of the Extracellular Matrix by Endothelial Cell-Targeting siRNA Improves the EPR-Based Delivery of 100 nm Particles. <i>Molecular Therapy</i> , 2016, 24, 2090-2099.	8.2	45
10	Efficient Short Interference RNA Delivery to Tumor Cells Using a Combination of Octaarginine, GALA and Tumor-Specific, Cleavable Polyethylene Glycol System. <i>Biological and Pharmaceutical Bulletin</i> , 2009, 32, 928-932.	1.4	43
11	Advances in an active and passive targeting to tumor and adipose tissues. <i>Expert Opinion on Drug Delivery</i> , 2015, 12, 41-52.	5.0	43
12	Effect of particle size on their accumulation in an inflammatory lesion in a dextran sulfate sodium (DSS)-induced colitis model. <i>International Journal of Pharmaceutics</i> , 2016, 509, 118-122.	5.2	43
13	Improvement of Doxorubicin Efficacy Using Liposomal Anti-Polo-like Kinase 1 siRNA in Human Renal Cell Carcinomas. <i>Molecular Pharmaceutics</i> , 2014, 11, 2713-2719.	4.6	41
14	Hepatic Monoacylglycerol O-acyltransferase 1 as a Promising Therapeutic Target for Steatosis, Obesity, and Type 2 Diabetes. <i>Molecular Therapy - Nucleic Acids</i> , 2014, 3, e154.	5.1	40
15	Targeting Tumor Endothelial Cells with Nanoparticles. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5819.	4.1	35
16	Modality of tumor endothelial VEGFR2 silencing-mediated improvement in intratumoral distribution of lipid nanoparticles. <i>Journal of Controlled Release</i> , 2017, 251, 1-10.	9.9	33
17	Development of lipid-like materials for RNA delivery based on intracellular environment-responsive membrane destabilization and spontaneous collapse. <i>Advanced Drug Delivery Reviews</i> , 2020, 154-155, 210-226.	13.7	33
18	Nano-sized drug carriers: Extravasation, intratumoral distribution, and their modeling. <i>Journal of Controlled Release</i> , 2017, 267, 31-46.	9.9	32

#	ARTICLE	IF	CITATIONS
19	Efficient siRNA Delivery by Lipid Nanoparticles Modified with a Nonstandard Macrocyclic Peptide for EpCAM-Targeting. <i>Molecular Pharmaceutics</i> , 2017, 14, 3290-3298.	4.6	28
20	Hyaluronan-modified nanoparticles for tumor-targeting. <i>Expert Opinion on Drug Delivery</i> , 2019, 16, 915-936.	5.0	27
21	Mitochondrial Delivery of an Anticancer Drug Via Systemic Administration Using a Mitochondrial Delivery System That Inhibits the Growth of Drug-Resistant Cancer Engrafted on Mice. <i>Journal of Pharmaceutical Sciences</i> , 2020, 109, 2493-2500.	3.3	26
22	A liposomal delivery system that targets liver endothelial cells based on a new peptide motif present in the ApoB-100 sequence. <i>International Journal of Pharmaceutics</i> , 2013, 456, 195-201.	5.2	24
23	Innovative Technologies in Nanomedicines: From Passive Targeting to Active Targeting/From Controlled Pharmacokinetics to Controlled Intracellular Pharmacokinetics. <i>Macromolecular Bioscience</i> , 2017, 17, 1600179.	4.1	23
24	Optimization of a siRNA Carrier Modified with a pH-Sensitive Cationic Lipid and a Cyclic RGD Peptide for Efficiently Targeting Tumor Endothelial Cells. <i>Pharmaceutics</i> , 2015, 7, 320-333.	4.5	22
25	Improved Stability of siRNA-Loaded Lipid Nanoparticles Prepared with a PEG-Monoacyl Fatty Acid Facilitates Ligand-Mediated siRNA Delivery. <i>Molecular Pharmaceutics</i> , 2020, 17, 1397-1404.	4.6	22
26	Ligand density at the surface of a nanoparticle and different uptake mechanism: Two important factors for successful siRNA delivery to liver endothelial cells. <i>International Journal of Pharmaceutics</i> , 2014, 475, 227-237.	5.2	21
27	Mitochondrial Delivery of Doxorubicin Using MITO-Porter Kills Drug-Resistant Renal Cancer Cells via Mitochondrial Toxicity. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2428-2437.	3.3	21
28	Delivery of Oligonucleotides Using a Self-Degradable Lipid-Like Material. <i>Pharmaceutics</i> , 2021, 13, 544.	4.5	20
29	Effective Therapy Using a Liposomal siRNA that Targets the Tumor Vasculature in a Model Murine Breast Cancer with Lung Metastasis. <i>Molecular Therapy - Oncolytics</i> , 2018, 11, 102-108.	4.4	19
30	Anti-angiogenic nanotherapy via active targeting systems to tumors and adipose tissue vasculature. <i>Biomaterials Science</i> , 2015, 3, 1253-1265.	5.4	18
31	The Delivery of Small Interfering RNA to Hepatic Stellate Cells Using a Lipid Nanoparticle Composed of a Vitamin A-Scaffold Lipid-Like Material. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2046-2052.	3.3	17
32	Modifying Cationic Liposomes with Cholesteryl-PEG Prevents Their Aggregation in Human Urine and Enhances Cellular Uptake by Bladder Cancer Cells. <i>Biological and Pharmaceutical Bulletin</i> , 2017, 40, 234-237.	1.4	17
33	Synergistic Enhancement of Cellular Uptake With CD44-Expressing Malignant Pleural Mesothelioma by Combining Cationic Liposome and Hyaluronic Acid-Lipid Conjugate. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 3218-3224.	3.3	14
34	Construction of an Aptamer Modified Liposomal System Targeted to Tumor Endothelial Cells. <i>Biological and Pharmaceutical Bulletin</i> , 2014, 37, 1742-1749.	1.4	13
35	Protecting liver sinusoidal endothelial cells suppresses apoptosis in acute liver damage. <i>Hepatology Research</i> , 2016, 46, 697-706.	3.4	13
36	Novel antiangiogenic therapy targeting biglycan using tumor endothelial cell-specific liposomal siRNA delivery system. <i>Cancer Science</i> , 2022, 113, 1855-1867.	3.9	12

#	ARTICLE	IF	CITATIONS
37	Silencing of VEGFR2 by RGD-Modified Lipid Nanoparticles Enhanced the Efficacy of Anti-PD-1 Antibody by Accelerating Vascular Normalization and Infiltration of T Cells in Tumors. <i>Cancers</i> , 2020, 12, 3630.	3.7	11
38	Improvement of mRNA Delivery Efficiency to a T Cell Line by Modulating PEG-Lipid Content and Phospholipid Components of Lipid Nanoparticles. <i>Pharmaceutics</i> , 2021, 13, 2097.	4.5	11
39	Liver-Specific Silencing of Lipin1 Reduces Fat Mass as Well as Hepatic Triglyceride Biosynthesis in Mice. <i>Biological and Pharmaceutical Bulletin</i> , 2016, 39, 1653-1661.	1.4	10
40	Development of Sentinel LN Imaging with a Combination of HAase Based on a Comprehensive Analysis of the Intra-lymphatic Kinetics of LPs. <i>Molecular Therapy</i> , 2021, 29, 225-235.	8.2	10
41	New drug delivery system for liver sinusoidal endothelial cells for ischemia-reperfusion injury. <i>World Journal of Gastroenterology</i> , 2015, 21, 12778.	3.3	10
42	Involvement of Caveolin-1-mediated transcytosis in the intratumoral accumulation of liposomes. <i>Biochemical and Biophysical Research Communications</i> , 2020, 525, 313-318.	2.1	9
43	Targeted delivery of lipid nanoparticle to lymphatic endothelial cells via anti-podoplanin antibody. <i>Journal of Controlled Release</i> , 2022, 349, 379-387.	9.9	9
44	Efficient Packaging of Plasmid DNA Using a pH Sensitive Cationic Lipid for Delivery to Hepatocytes. <i>Biological and Pharmaceutical Bulletin</i> , 2015, 38, 1185-1191.	1.4	6
45	Development on Rubber Bearings for Sodium-Cooled Fast Reactor: Part 2 " Fundamental Characteristics of Half-Scale Rubber Bearings Based on Static Test. , 2015, , .		6
46	Optimization of Sentinel Lymph Node Imaging Methodology Using Anionic Liposome and Hyaluronidase. <i>Pharmaceutics</i> , 2021, 13, 1462.	4.5	6
47	Research and Development of Rubber Bearings for Sodium-Cooled Fast Reactor: Ultimate Properties of Half-Scale Thick Rubber Bearings Based on Breaking Tests. <i>Journal of Pressure Vessel Technology, Transactions of the ASME</i> , 2018, 140, .	0.6	6
48	Preparation of a Cyclic RGD: Modified Liposomal siRNA Formulation for Use in Active Targeting to Tumor and Tumor Endothelial Cells. <i>Methods in Molecular Biology</i> , 2016, 1364, 63-69.	0.9	5
49	Failure of active targeting by a cholesterol-anchored ligand and improvement by altering the lipid composition to prevent ligand desorption. <i>International Journal of Pharmaceutics</i> , 2018, 536, 42-49.	5.2	4
50	Scalable preparation of poly(ethylene glycol)-grafted siRNA-loaded lipid nanoparticles using a commercially available fluidic device and tangential flow filtration. <i>Journal of Biomaterials Science, Polymer Edition</i> , 2017, 28, 1086-1096.	3.5	3
51	A complicated interpretation of a therapeutic effect with humanized mice using a novel peptide platform. <i>Biotarget</i> , 0, 1, 4-4.	0.5	3
52	EPR effect and development of new strategy for nanoparticle delivery via remodeling tumor microenvironment based on tumor vasculature targeting. <i>Drug Delivery System</i> , 2018, 33, 98-104.	0.0	1
53	Proteomics Analysis of Lymphatic Metastasis-Related Proteins Using Highly Metastatic Human Melanoma Cells Originated by Sequential <i>in Vivo</i> Implantation. <i>Biological and Pharmaceutical Bulletin</i> , 2021, 44, 1551-1556.	1.4	0
54	Anti-angiogenic Therapy by Targeting the Tumor Vasculature with Liposomes. <i>Fundamental Biomedical Technologies</i> , 2016, , 201-228.	0.2	0